The Chronic Spontaneous Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Chronic Spontaneous Urticaria Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Spontaneous Urticaria Market.
Some of the key takeaways from the Chronic Spontaneous Urticaria Pipeline Report:
- Companies across the globe are diligently working toward developing novel Chronic Spontaneous Urticaria treatment therapies with a considerable amount of success over the years.
- Chronic Spontaneous Urticaria companies working in the treatment market are Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Novartis, and others, are developing therapies for the Chronic Spontaneous Urticaria treatment
- Emerging Chronic Spontaneous Urticaria therapies in the different phases of clinical trials are- YH35324, TLL018, CDX-0159, UB-221, Tezepelumab, CT-P39, LOU064, and others are expected to have a significant impact on the Chronic Spontaneous Urticaria market in the coming years.
- In October 2023, The FDA has approved Jasper Therapeutics Inc.'s investigational new drug (IND) application for a Phase 1b/2a repeat dose clinical study of subcutaneous briquilimab in the treatment of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Jasper is a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases, as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens.
- In August 2023, A Bruton's tyrosine kinase (BTK) inhibitor called remibrutinib 25 mg b.i.d. was tested on individuals with chronic spontaneous urticaria (CSU) whose symptoms are not well managed by H1-antihistamines. Positive top-line outcomes from these Phase III trials were released by Novartis.
- In June 2023, "A Double-blind, Randomized, Placebo Controlled Trial to Assess the Efficacy, Pharmacokinetics and Safety of Remibrutinib (LOU064) for 24 Weeks in Adolescents From 12 to Less Than 18 Years of Age With Chronic Spontaneous Urticaria Inadequately Controlled byH1-antihistamines Followed by an Optional Open-label Extension for up to Another 3 Years and an Optional Safety Monitoring," was announced by Novartis Pharmaceuticals.Prolonged Monitoring without Intervention for Up to Three Years
- In December 2022, "A Double-blind, Randomized, Placebo Controlled Trial to Assess the Efficacy, Pharmacokinetics and Safety of Remibrutinib (LOU064) for 24 Weeks in Adolescents From 12 to Less Than 18 Years of Age With Chronic Spontaneous Urticaria Inadequately Controlled byH1-antihistamines Followed by an Optional Open-label Extension for up to Another 3 Years and an Optional Safety Monitoring," was announced by Novartis Pharmaceuticals.Prolonged Monitoring without Intervention for Up to Three Years
- In October 2022, Remibrutinib was found to be very efficient in treating mild to severe chronic spontaneous urticaria; it also had a speedy beginning of action and a great safety profile, according to research published in The Journal of Allergy & Clinical Immunology.
Chronic Spontaneous Urticaria Overview
Hives that persist for most days of the week and for at least six weeks are classified as Chronic Spontaneous Urticaria (CSU). The pathogenic activation of basophils and mast cells leads to the release of proinflammatory mediators that exacerbate urticaria and cause CSU.
Get a Free Sample PDF Report to know more about Chronic Spontaneous Urticaria Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight
Emerging Chronic Spontaneous Urticaria Drugs Under Different Phases of Clinical Development Include:
- YH35324: Yuhan Corporation
- TLL018: Hangzhou Highlightll Pharmaceutical Co., Ltd
- CDX-0159: Celldex Therapeutics
- UB-221: United BioPharma
- Tezepelumab: Amgen
- CT-P39: Celltrion
- LOU064: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria Route of Administration
Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Chronic Spontaneous Urticaria Molecule Type
Chronic Spontaneous Urticaria Products have been categorized under various Molecule types, such as
- Monoclonal antibody
- Small molecule
- Peptide
Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment
- Chronic Spontaneous Urticaria Assessment by Product Type
- Chronic Spontaneous Urticaria By Stage and Product Type
- Chronic Spontaneous Urticaria Assessment by Route of Administration
- Chronic Spontaneous Urticaria By Stage and Route of Administration
- Chronic Spontaneous Urticaria Assessment by Molecule Type
- Chronic Spontaneous Urticaria by Stage and Molecule Type
DelveInsight's Chronic Spontaneous Urticaria Report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Chronic Spontaneous Urticaria product details are provided in the report. Download the Chronic Spontaneous Urticaria pipeline report to learn more about the emerging Chronic Spontaneous Urticaria therapies
Some of the key companies in the Chronic Spontaneous Urticaria Therapeutics Market include:
Key companies developing therapies for Chronic Spontaneous Urticaria are - GlaxoSmithKline, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Synermore Biologics, UCB Biopharma, United BioPharma, and others.
Chronic Spontaneous Urticaria Pipeline Analysis:
The Chronic Spontaneous Urticaria pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Spontaneous Urticaria with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Spontaneous Urticaria Treatment.
- Chronic Spontaneous Urticaria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Chronic Spontaneous Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Spontaneous Urticaria market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Chronic Spontaneous Urticaria drugs and therapies
Chronic Spontaneous Urticaria Pipeline Market Drivers
- Increasing prevalence of Chronic Spontaneous Urticaria, development of Novel Treatments are some of the important factors that are fueling the Chronic Spontaneous Urticaria Market.
Chronic Spontaneous Urticaria Pipeline Market Barriers
- However, difficulty in identifying the condition, lack of awareness about the treatment and other factors are creating obstacles in the Chronic Spontaneous Urticaria Market growth.
Scope of Chronic Spontaneous Urticaria Pipeline Drug Insight
- Coverage: Global
- Key Chronic Spontaneous Urticaria Companies: Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Novartis, and others
- Key Chronic Spontaneous Urticaria Therapies: YH35324, TLL018, CDX-0159, UB-221, Tezepelumab, CT-P39, LOU064, and others
- Chronic Spontaneous Urticaria Therapeutic Assessment: Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
- Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria market drivers and Chronic Spontaneous Urticaria market barriers
Request for Sample PDF Report for Chronic Spontaneous Urticaria Pipeline Assessment and clinical trials
Table of Contents
1. Chronic Spontaneous Urticaria Report Introduction
2. Chronic Spontaneous Urticaria Executive Summary
3. Chronic Spontaneous Urticaria Overview
4. Chronic Spontaneous Urticaria- Analytical Perspective In-depth Commercial Assessment
5. Chronic Spontaneous Urticaria Pipeline Therapeutics
6. Chronic Spontaneous Urticaria Late Stage Products (Phase II/III)
7. Chronic Spontaneous Urticaria Mid Stage Products (Phase II)
8. Chronic Spontaneous Urticaria Early Stage Products (Phase I)
9. Chronic Spontaneous Urticaria Preclinical Stage Products
10. Chronic Spontaneous Urticaria Therapeutics Assessment
11. Chronic Spontaneous Urticaria Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Spontaneous Urticaria Key Companies
14. Chronic Spontaneous Urticaria Key Products
15. Chronic Spontaneous Urticaria Unmet Needs
16 . Chronic Spontaneous Urticaria Market Drivers and Barriers
17. Chronic Spontaneous Urticaria Future Perspectives and Conclusion
18. Chronic Spontaneous Urticaria Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
